2. Summary of reported outcomes.
| Live birth | Pre‐eclampsia | Maternal bleeding |
Thrombo cytopenia |
Allergic Reactions |
VTE ATE | Preterm delivery | IUGR |
Congenital Malformations |
Neonatal Bleeding |
|||||||||||
| Studies | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B |
| Alalaf 2012 | 69/80 | 44/61 | 1/69 | 0/44 | 5/81 | NA | NA | NA | NA | NA | 0/80 | 0/61 | 3/69 | 2/44 | NA | NA | NA | NA | NA | NA |
| Bao 2017 | 449/497 | 363/518 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Farquharson 2002 | 40/51 | 34/47 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2/40 | 4/34 | NA | NA | NA | NA | NA | NA |
| Fouda 2010 | 23/30 | 21/30 | 3/30 | 2/30 | 0/30 | 0/30 | 0/30 | 0/30 | NA | NA | 0/30 | 0/30 | 3/23 | 2/21 | 2/30 | 1/30 | 0/23 | 0/21 | 0/23 | 0/21 |
| Fouda 2011* | 24/30 | 20/30 | 2/24 | 1/20 | 0/30 3/30 |
0/30 3/30 |
0/30 | 0/30 | 0/30 | 1/30 | 0/30 | 0/30 | 3/24 | 2/20 | 1/24 | 2/20 | 0/24 | 0/20 | 0/24 | 0/20 |
| Kutteh 1996a** | 20/25 | 11/25 | 2/20 | 1/11 | 0/20 3/20 |
0/11 1/11 |
0/25 | 0/25 | NA | NA | 0/25 | 0/25 | 3/20 | 1/11 | 3/20 | 1/11 | NA | NA | NA | NA |
| Kutteh 1996b** | 20/25 | 19/25 | 2/20 | 1/19 | 0/20 3/20 |
0/19 4/19 |
0/25 | 0/25 | NA | NA | NA | NA | 3/20 | 1/19 | 3/20 | 0/19 | NA | NA | NA | NA |
| Laskin 2009 | 17/22 | 15/20 | NA | NA | NA | NA | NA | NA | NA | NA | 0/22 | 0/20 | NA | NA | NA | NA | NA | NA | NA | NA |
| Pattison 2000 | 16/20 | 17/20 | 3/16 | 3/17 | 9/20 | 7/20 | NA | NA | NA | NA | NA | NA | 2/16 | 0/17 | 1/16 | 4/17 | 1/16 | 1/17 | NA | NA |
| Rai 1997 | 32/45 | 19/45 | 0/32 | 1/19 | 0/45 | NA | 0/45 | NA | 0/45 | NA | 0/45 | 0/45 | 8/32 | 4/19 | 3/32 | 1/19 | 0/32 | 0/19 | NA | NA |
| Stephenson 2004 | 9/13 | 4/13 | 1/13 | 0/13 | 0/13 | 0/13 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
ATE: arterial thromboembolism;LMWH: low‐molecular weight heparin; NA: outcome not assessed; UFH: unfractionated heparin; VTE: venous thromboembolism.
- Alalaf 2012: group A = LMWH, group B = aspirin
- Bao 2017: group A = LMWH + aspirin, group B = aspirin
- Farquharson 2002: group A = LMWH + aspirin, group B = aspirin
- Fouda 2010: group A = high‐dose LMWH plus aspirin, group B = low‐dose LMWH plus aspirin
- Fouda 2011: group A = LMWH + aspirin, group B = UFH + aspirin, *no bleeding in either group, subcutaneous bruising 3/30 in both group
- Kutteh 1996a: group A = UFH + aspirin, group B = aspirin; **no major bleeding, reports are minor bleeding events
- Kutteh 1996b: group A = high‐dose UFH plus aspirin, group B = low‐dose UFH + aspirin; **no major bleeding events, reports are minor bleeding events
- Laskin 2009: group A = LMWH + aspirin, group B = aspirin
- Pattison 2000: group A = aspirin, group B = placebo
- Rai 1997: group A = UFH + aspirin, group B = aspirin
- Stephenson 2004: group A = LMWH + aspirin, group B = UFH + aspirin